• Mutation; VGNC; 42422; KIT; Simple; p.Val558_Glu560del (c.1673_1681delTTGTTGAGG); Zygosity=Heterozygous (PubMed=31175136).
  

PubMed=15965647; DOI=10.1007/s00262-005-0025-6; PMCID=PMC11031070
Alexander A.N., Huelsmeyer M.K., Mitzey A., Dubielzig R.R., Kurzman I.D., MacEwen E.G., Vail D.M.
Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma.
Cancer Immunol. Immunother. 55:433-442(2006)

PubMed=22901430; DOI=10.1016/j.jcpa.2012.07.001; PMCID=PMC3535688
Chon E., Thompson V., Schmid S., Stein T.J.
Activation of the canonical Wnt/beta-catenin signalling pathway is rare in canine malignant melanoma tissue and cell lines.
J. Comp. Pathol. 148:178-187(2013)

PubMed=27257868; DOI=10.1371/journal.pone.0156689; PMCID=PMC4892608
Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.
Intrinsic radiosensitivity and cellular characterization of 27 canine cancer cell lines.
PLoS ONE 11:E0156689-E0156689(2016)

PubMed=27197945; DOI=10.1111/vco.12192; PMCID=PMC5656225
Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.
The Flint Animal Cancer Center (FACC) canine tumour cell line panel: a resource for veterinary drug discovery, comparative oncology and translational medicine.
Vet. Comp. Oncol. 15:481-492(2017)

PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346; PMCID=PMC6679748
Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.
Identifying candidate druggable targets in canine cancer cell lines using whole-exome sequencing.
Mol. Cancer Ther. 18:1460-1471(2019)